Literature DB >> 27277477

Correlation between prostate volume and single nucleotide polymorphisms implicated in the steroid pathway.

Jean-Nicolas Cornu1,2, Etienne Audet-Walsh3, Sarah Drouin4,5, Pierre Bigot6, Antoine Valeri7,8, Georges Fournier7,8, Abdel-Rahmène Azzouzi6,8, Morgan Roupret4,5,8, Luc Cormier8,9, Stephen Chanock10, Chantal Guillemette3, Olivier Cussenot11,4,8, Eric Lévesque3, Géraldine Cancel-Tassin4,8.   

Abstract

OBJECTIVES: A few preliminary studies have suggested a link between some genetics variants and benign prostatic hyperplasia (BPH). Our goal was to study the link between a set of single nucleotide polymorphisms (SNPs) implicated in the steroid pathway and accurate measurement of prostate volume in a cohort of men who underwent radical prostatectomy.
METHODS: Clinical and pathological data including prostate weight were obtained from 611 Caucasian patients with small volume, localized prostate cancer treated by radical prostatectomy. Patients were genotyped for 90 SNPs located inside or nearby genes implicated in the steroid pathway (Sequenom iPLEX). Correlation between prostate weight and genotypes from each SNP was studied by analysis of covariance, adjusted on age and tumor stage. A Bonferroni correction was applied, and the SNPs implicated were then incorporated in a multivariable model. RESULTS AND LIMITATIONS: Seven SNPs located in or nearby genes implicated in steroid hormone metabolism were significantly associated with prostate volume: HSD17B2 (rs1119933), ESR2 (rs8006145), SULT2B1 (rs279451), NQO1 (rs2917670), ESR1 (rs1569788), GSTP1 (rs1138272), and CYP19A1 (rs17523880). Significant association was maintained after multivariate analysis for four SNPs, indicating their independent association with prostate volume. The power of the association of each SNP with prostate volume was comparable to the effect of age. The strongest associations were found with variants in ESR1, ESR2, HSD17B2, and CYP19A1 genes, indicating a potential role of the estrogen signaling pathway in genesis of BPH.
CONCLUSIONS: Our results are in favor of an implication of estrogen biotransformation and signaling pathways in the pathophysiology of BPH.

Entities:  

Keywords:  Prostate weight; Prostatectomy; Single nucleotide polymorphisms; Steroid pathway

Mesh:

Substances:

Year:  2016        PMID: 27277477     DOI: 10.1007/s00345-016-1869-4

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  35 in total

1.  Elevated androgens and prolactin in aromatase-deficient mice cause enlargement, but not malignancy, of the prostate gland.

Authors:  S J McPherson; H Wang; M E Jones; J Pedersen; T P Iismaa; N Wreford; E R Simpson; G P Risbridger
Journal:  Endocrinology       Date:  2001-06       Impact factor: 4.736

Review 2.  Androgens and estrogens in benign prostatic hyperplasia: past, present and future.

Authors:  Tristan M Nicholson; William A Ricke
Journal:  Differentiation       Date:  2011-05-26       Impact factor: 3.880

3.  The impact of germline genetic variations in hydroxysteroid (17-beta) dehydrogenases on prostate cancer outcomes after prostatectomy.

Authors:  Étienne Audet-Walsh; Judith Bellemare; Louis Lacombe; Yves Fradet; Vincent Fradet; Pierre Douville; Chantal Guillemette; Éric Lévesque
Journal:  Eur Urol       Date:  2011-12-21       Impact factor: 20.096

Review 4.  Role of interleukins, IGF and stem cells in BPH.

Authors:  Ian D McLaren; Travis J Jerde; Wade Bushman
Journal:  Differentiation       Date:  2011-08-23       Impact factor: 3.880

5.  A role for estrogen receptor beta in the regulation of growth of the ventral prostate.

Authors:  Z Weihua; S Makela; L C Andersson; S Salmi; S Saji; J I Webster; E V Jensen; S Nilsson; M Warner; J A Gustafsson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-22       Impact factor: 11.205

Review 6.  Estrogen and androgen signaling in the pathogenesis of BPH.

Authors:  Clement K M Ho; Fouad K Habib
Journal:  Nat Rev Urol       Date:  2011-01       Impact factor: 14.432

7.  Clinical and biological characteristics of familial benign prostatic hyperplasia.

Authors:  M G Sanda; C B Doehring; B Binkowitz; T H Beaty; A W Partin; E Hale; E Stoner; P C Walsh
Journal:  J Urol       Date:  1997-03       Impact factor: 7.450

8.  Oestrogen and benign prostatic hyperplasia: effects on stromal cell proliferation and local formation from androgen.

Authors:  Clement K M Ho; Jyoti Nanda; Karen E Chapman; Fouad K Habib
Journal:  J Endocrinol       Date:  2008-06       Impact factor: 4.286

9.  Association between polymorphisms of estrogen receptor 2 and benign prostatic hyperplasia.

Authors:  Su Kang Kim; Joo-Ho Chung; Hyun Chul Park; Jun Ho Kim; Jae Hong Ann; Hun Kuk Park; Sang Hyup Lee; Koo Han Yoo; Byung-Cheol Lee; Young Ock Kim
Journal:  Exp Ther Med       Date:  2015-09-21       Impact factor: 2.447

10.  Genetic Determinants of Metabolism and Benign Prostate Enlargement: Associations with Prostate Volume.

Authors:  Ayush Giri; Todd L Edwards; Saundra S Motley; Susan H Byerly; Jay H Fowke
Journal:  PLoS One       Date:  2015-07-09       Impact factor: 3.240

View more
  5 in total

1.  A genetic variant near GATA3 implicated in inherited susceptibility and etiology of benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS).

Authors:  Rong Na; Brian T Helfand; Haitao Chen; Carly A Conran; Susan E Crawford; Simon W Hayward; Teuvo L J Tammela; Judy Hoffman-Bolton; Siqun L Zheng; Patrick C Walsh; Johanna Schleutker; Elizabeth A Platz; William B Isaacs; Jianfeng Xu
Journal:  Prostate       Date:  2017-06-28       Impact factor: 4.104

2.  Genome-wide associations for benign prostatic hyperplasia reveal a genetic correlation with serum levels of PSA.

Authors:  Julius Gudmundsson; Jon K Sigurdsson; Lilja Stefansdottir; Bjarni A Agnarsson; Helgi J Isaksson; Olafur A Stefansson; Sigurjon A Gudjonsson; Daniel F Gudbjartsson; Gisli Masson; Michael L Frigge; Simon N Stacey; Patrick Sulem; Gisli H Halldorsson; Vinicius Tragante; Hilma Holm; Gudmundur I Eyjolfsson; Olof Sigurdardottir; Isleifur Olafsson; Thorvaldur Jonsson; Eirikur Jonsson; Rosa B Barkardottir; Rafn Hilmarsson; Folkert W Asselbergs; Gudmundur Geirsson; Unnur Thorsteinsdottir; Thorunn Rafnar; Gudmar Thorleifsson; Kari Stefansson
Journal:  Nat Commun       Date:  2018-11-08       Impact factor: 14.919

3.  The single nucleotide polymorphism rs700518 is an independent risk factor for metabolic syndrome and benign prostatic hyperplasia (MetS-BPH).

Authors:  Z P Chen; Y Yan; C J Chen; M Li; C Chen; S C Zhao; T Song; T Liu; C H Zou; Q Xu; X Li
Journal:  Andrology       Date:  2018-06-05       Impact factor: 3.842

4.  The role of CYP19A1 and ESR2 gene polymorphisms in female androgenetic alopecia in the Polish population.

Authors:  Adriana Łukasik; Karolina Kozicka; Aleksandra Pisarek; Anna Wojas-Pelc
Journal:  Postepy Dermatol Alergol       Date:  2021-08-16       Impact factor: 1.664

5.  GSTP1 rs1138272 Polymorphism Affects Prostate Cancer Risk.

Authors:  Veljko Santric; Milica Djokic; Sonja Suvakov; Marija Pljesa-Ercegovac; Marina Nikitovic; Tanja Radic; Miodrag Acimovic; Vesna Stankovic; Uros Bumbasirevic; Bogomir Milojevic; Uros Babic; Zoran Dzamic; Tatjana Simic; Dejan Dragicevic; Ana Savic-Radojevic
Journal:  Medicina (Kaunas)       Date:  2020-03-13       Impact factor: 2.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.